Liver Disease Therapeutics
•12 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (12)
| Company | Market Cap | Price |
|---|---|---|
|
GILD
Gilead Sciences, Inc.
Livdelzi (seladelpar) targets liver disease (PBC), aligning with Liver Disease Therapeutics.
|
$150.19B |
$120.75
-0.58%
|
|
MDGL
Madrigal Pharmaceuticals, Inc.
Liver disease therapeutics is a broad, investable theme that encompasses the NAFLD/NASH treatment market, which Madrigal targets with Rezdiffra.
|
$9.41B |
$424.25
+2.00%
|
|
VKTX
Viking Therapeutics, Inc.
VK2809 is a liver-selective TRβ agonist targeting NASH/fibrosis, a liver disease therapeutics program.
|
$3.81B |
$33.92
+7.97%
|
|
MIRM
Mirum Pharmaceuticals, Inc.
Core business includes liver disease therapeutics, with LIVMARLI and CTEXLI and acquired bile acid medications.
|
$3.45B |
$69.36
-0.34%
|
|
KRRO
Korro Bio, Inc.
Delivery approach GalNAc liver-targeting implies liver disease/hepatic targeting therapeutics.
|
$381.35M |
$37.41
-7.88%
|
|
DCTH
Delcath Systems, Inc.
Platform aims to treat liver-dominant cancers, aligning with the Liver Disease Therapeutics investable theme.
|
$361.50M |
$10.35
-0.10%
|
|
SLN
Silence Therapeutics plc
Divesiran targets pathways related to liver iron metabolism and PV, aligning with liver disease therapeutics.
|
$341.97M |
$7.19
-0.14%
|
|
IVA
Inventiva S.A.
Lanifibranor targets a liver-disease indication (MASH/NASH), aligning with the 'Liver Disease Therapeutics' tag.
|
$308.04M |
$5.79
+8.32%
|
|
GNFT
Genfit S.A.
GENFIT's ELAFIBRONOR in Primary Biliary Cholangitis (PBC) represents a core liver-disease therapeutic offering.
|
$214.60M |
N/A
|
|
KZR
Kezar Life Sciences, Inc.
Kezar’s AIH program targets a liver disease indication, fitting the Liver Disease Therapeutics theme.
|
$44.93M |
$6.17
|
|
SBFM
Sunshine Biopharma, Inc.
K1.1 mRNA liver cancer program places the company in liver disease therapeutics.
|
$8.38M |
$1.85
+0.54%
|
|
CANF
Can-Fite BioPharma Ltd.
Namodenoson targets liver disease indications (NAFLD/NASH and hepatocellular carcinoma).
|
$2.50M |
$0.49
-2.20%
|
Loading industry trends...
Loading research report...
